RARA CRAFT DATABASE for FDA Medical Devices
510(k)K241115

FDA DEVICE FACTS

SV Spectrum MRC Central Venous Catheter; SV Spectrum MR Central Venous Catheter; SV Central Venous Catheter

Spectrum Vascular

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATENovember 27, 2024PRODUCT CODEFOZ

Indications for use

The SV Spectrum MRC Central Venous Catheter is indicated to provide short-term (<30 days) central venous access intended for:

• Continuous or intermittent drug infusion

• Central venous blood pressure monitoring (CVP)

• Acute hyperalimentation

• Blood sampling

• Delivery of whole blood or blood products

• Simultaneous, separate infusion of drugs

• Power injection of contrast media (max 300 psi) The activity of the antimicrobial agents, minocycline, rifampin and chlorhexidine is located at the internal and external catheter surfaces and is not intended for treatment of existing infections. This combination of antimicrobials has been shown to reduce microbial colonization of the catheter. The effectiveness was evaluated using in vitro methods; no correlation between in vitro and clinical outcome has currently been ascertained. Controlled studies of this product have not been conducted in pregnant women, pediatric or neonatal patients. The benefits of the use of this catheter should be weighed against any possible risk. Consider CDC Guidelines and institutional protocols for catheter exchange. The SV Spectrum MR Central Venous Catheter is indicated to provide short-term (<30 days) central venous access intended for:

• Continuous or intermittent drug infusion

• Central venous blood pressure monitoring (CVP)

• Acute hyperalimentation

• Blood sampling

• Delivery of whole blood or blood products

• Simultaneous, separate infusion of drugs and

• Power injection of contrast media (max 300 psi). The activity of the antimicrobial agents, minocycline and rifampin is localized at the internal and external catheter surfaces and helps to provide protection against catheter related bloodstream infections (CRBSI). It is not intended for treatment of existing infection. The device is a short- term use catheter. The SV Central Venous Catheter is indicated to provide short- term (<30 days) central venous access intended for:

• Continuous or intermittent drug infusion

• Central venous blood pressure monitoring (CVP)

• Acute hyperalimentation

• Blood sampling

• Delivery of whole blood or blood products

• Simultaneous, separate infusion of drugs and

• Power injection of contrast media (max 300 psi).

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 11, 2026